Skip to main content

Luxembourg Cancer Institute Launches Precision Oncology Study

NEW YORK (GenomeWeb) — Luxembourg's Institut National du Cancer (INC) announced today that it has begun an initiative to evaluate the use of molecular diagnostics in cancer treatment.

Called MDLUX2, the three-year program — which is being sponsored by the Fondation Cancer, the Fondatioun Kriibskrank Kanner, and Integrated BioBank of Luxembourg (IBBL) — will use a standardized set of molecular diagnostics to analyze tissue samples from hundreds of cancer patients recruited through local hospitals. The resulting data will be used to characterize the mutations driving patients' tumors and inform treatment decisions.

"The project seeks to guide clinicians in their choice of the most appropriate treatment to be administered to each individual patient," INC Coordinator Nikolai Goncharenko said in a statement. "Our goal is to improve clinical outcomes for patients whilst strengthening Luxembourg's position with respect to molecular diagnostics, personalized medicine, and cancer research."

Belgian precision medicine firm OncoDNA will provide molecular diagnostic services and its OncoKDM data interpretation and reporting platform to MDLUX2. Remaining tissue and associated clinical data will be stored at IBBL and made available for future research, pending patient consent.